X0508 4 2025-12-05 0 0001802768 Royalty Pharma plc RPRX 0001838139 Urist Marshall C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET NEW YORK NY 10022 0 1 0 0 EVP, Research & Investments 1 Class A Ordinary Shares 2025-12-05 4 S 0 23334 39.1528 D 160000 I By Sandy Lamm LLC Class A Ordinary Shares 2025-12-05 4 S 0 18242 39.1527 D 7398 D Class A Ordinary Shares 19020 I By IRA All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 2,474,120 Class A Ordinary Shares. The Reporting Person also holds 1,356,528 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares. /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist 2025-12-09